BioSpace News Archive

Anebulo Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2023, and recent updates.

UroGen Pharma Ltd. today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments.

OliX Pharmaceuticals, Inc. today announced that the Company presented its latest study data from preclinical studies identifying synergistic effects in weight loss when using its non-alcoholic steatohepatitis (NASH) treatment candidate OLX702A in combination with semaglutide.

Forge Biologics will be delivered during the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy.

Axis Research & Technologies, a premier bioskills training and cadaver lab supporting medical device research and testing, announced the integration of OMNIMED™ SmartOR™ across its four locations.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults.

Grifols announced it has launched its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of alpha1-antitrypsin deficiency.

Femasys Inc. today announced that the Company’s management team will be attending the annual American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM) being held May 19-21, 2023 in Baltimore, Maryland.

ChromaDex Corp. today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference.

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest.